Clinical trials: Acquired Immune Deficiency Syndrome
Meningitis, Cryptococcal, HIV Infections
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients.
- Trial name
- NCT00002040
- Testing
- Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
HIV, AIDS
TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
The purpose of this study is to investigate the pharmacokinetic interaction between the combination of ethinylestradiol and norethindrone and TMC278 25 mg once daily.
- Conditions
- HIV, AIDS, Oral Contraceptive
- Trial name
- NCT00739622
- Testing
- TMC278
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections, AIDS Virus
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir
The purpose of the study is to compare the efficacy, safety and tolerability of darunavir/ritonavir 800/100 mg once a day (O.D.) as a monotherapy versus a triple combination therapy containing 2 nucleosides and…
- Conditions
- HIV Infections, AIDS Virus, Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome Virus
- Trial name
- MONET (NCT00458302)
- Testing
- darunavir (DRV, TMC114)
- Where
- 27 sites in Austria, Belgium and 9 more
- Volunteers
- 256 people
- Sponsor
- Janssen-Cilag International NV
Human Immunodeficiency Virus Infection
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
This is a double-blind Phase 2a study to test the safety and efficacy of an investigational HIV drug, amdoxovir (300 mg or 500 mg twice daily) compared with tenofovir DF 300 mg once daily in HIV-1 infected antiretroviral…
- Trial name
- NCT01737359
- Testing
- amdoxovir 300 mg bid, amdoxovir 500 mg bid, tenofovir DF 300 mg qd
- Where
- 6 sites in Argentina
- Volunteers
- 2 people
- Sponsor
- RFS Pharma, LLC
Chronic Disease, HIV/AIDS
Observational Pharmaco-Epidemiology Research & Analysis
Greater advances are needed in two separate but related areas in healthcare: 1) the Clinical Decision Support Systems that complement the EHR use in support of routine patient care, population management and disease management…
- Conditions
- Chronic Disease, HIV/AIDS, Liver Diseases, Inflammatory Bowel Diseases
- Trial name
- OPERA (NCT03813862)
- Testing
- Non-interventional (observational only)
- Where
- United States
- Volunteers
- 2,000,000 people, healthy volunteers welcome
- Sponsor
- Epividian
Cytomegalovirus Retinitis, HIV Infections
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
To determine whether co-administration of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) improves tolerance to ganciclovir in patients previously intolerant because of neutropenia defined as an absolute…
- Trial name
- NCT00002070
- Testing
- Sargramostim, Ganciclovir
- Where
- 14 sites in United States
- Sponsor
- Schering-Plough
Hepatitis B, Human Immunodeficiency Virus
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.
- Conditions
- Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
- Trial name
- NCT00782301
- Testing
- maraviroc, etravirine
- Where
- 18 sites in United States, Canada and 1 more
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations
This trial is a randomized, double-blind, placebo-controlled clinical study conducted in treatment-experienced adults with NNRTI-resistant HIV-1, designed to preliminarily evaluate the efficacy, safety, and resistance profile of…
- Trial name
- NCT07711210
- Testing
- ACC017
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Infection, Human Immunodeficiency Virus, HIV Infections
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to < 2 years…
- Trial name
- NCT00071760
- Testing
- GW433908, ritonavir
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 59 people
- Sponsor
- ViiV Healthcare
Herpes Simplex, HIV Infections
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients.
- Trial name
- NCT00002021
- Testing
- Foscarnet sodium
- Where
- 2 sites in United States
- Sponsor
- Astra USA
HIV Infections
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
PART I: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of three fixed doses of delavirdine mesylate (DLV) in combination with zidovudine (AZT) versus AZT alone in HIV-positive patients.
- Trial name
- NCT00002124
- Testing
- Delavirdine mesylate, Lamivudine, Zidovudine
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,250 people
- Sponsor
- Pharmacia and Upjohn
HIV Coinfection, Aids/Hiv Problem
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the…
- Conditions
- HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary, Human Immunodeficiency Virus
- Trial name
- MSPB_TB (NCT05065905)
- Testing
- Interferon-Gamma
- Where
- 2 sites in Russia
- Volunteers
- 78 people
- Sponsor
- SPP Pharmaclon Ltd.
Human Immunodeficiency Virus (HIV) Infection
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
This is a study of HB-502 and HB-501 alternating 2-vector therapy in people living with human immunodeficiency virus (HIV) who are taking antiretroviral treatment (ART).
- Trial name
- NCT06430905
- Testing
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hookipa Biotech GmbH
Infection, Human Immunodeficiency Virus
Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol
Dolutegravir (DTG, GSK1349572 is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of HIV infection. DTG will likely be used in women on oral contraceptives (OC) for birth control.
- Trial name
- NCT01498861
- Testing
- Ortho-Cyclen, Dolutegravir
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cytomegalovirus Infections, HIV Infections
Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
To provide ganciclovir on a compassionate use basis to immunocompromised patients with serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient population.
- Trial name
- NCT00002024
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Infection, Human Immunodeficiency Virus
A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
This study is a Phase I, open-label, single dose, mass balance study in a cohort of 6 healthy adult male subjects. The study will consist of: Screening evaluations, a treatment phase, and follow-up evaluations.
- Trial name
- NCT01273103
- Testing
- 200mg [14C]- GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Acquired Immunodeficiency Syndrome
A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)
To determine whether a regimen of single dose nevirapine combined with either 4 or 7 days of Combivir®, compared to a regimen of single dose nevirapine, for the prevention of mother to child transmission can reduce the rate of…
- Trial name
- NCT00144183
- Testing
- Nevirapine (NVP), Zidovudine (ZCV), 3TC
- Where
- 5 sites in South Africa
- Volunteers
- 407 people
- Sponsor
- Boehringer Ingelheim
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
- Conditions
- Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
- Trial name
- NCT04554914
- Testing
- Tabelecleucel
- Where
- 40 sites in United States, Austria and 5 more
- Volunteers
- 190 people
- Sponsor
- Pierre Fabre Medicament
Human Immunodeficiency Virus Infection
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
This study of Kaletra (Lopinavir (LPV)/Ritonavir (RTV)) tablets will be conducted to clarify the following with regard to treatment with this drug: 1.
- Trial name
- NCT01328158
- Where
- 23 sites in Japan
- Volunteers
- 236 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Human Immunodeficiency Virus - Type 1
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
The purpose of this study is to test if being treated with darunavir/ritonavir (DRV/rtv) 800/100 mg daily is as effective as being treated with DRV/rtv 600/100 mg twice daily, in early antiretroviral (ARV)-experienced patients…
- Trial name
- ODIN (NCT00524368)
- Testing
- Darunavir (DRV), Ritonavir (rtv)
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 590 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland